Profile for Serbia Patent: 53811

US Patent Family Members and Approved Drugs for Serbia Patent: 53811

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,383,876	Mar 29, 2032	Bayer Healthcare	ALIQOPA	copanlisib dihydrochloride
9,636,344	Mar 29, 2032	Bayer Healthcare	ALIQOPA	copanlisib dihydrochloride

Key insights for pharmaceutical patentability - Serbia patent RS53811

Last updated: April 24, 2026

Scope, Claims, and Patent Landscape for RS53811 (Serbia)

No substantive patent scope or claim-set content is provided in the input for Serbia patent RS53811. Without the published specification, claim text, legal status record, or bibliographic data for RS53811, a complete and accurate analysis of scope, claim boundaries, and landscape positioning cannot be produced.

What does RS53811 cover?

No claim or description text for RS53811 is available in the provided material, so the therapeutic area, active ingredient(s), dosage forms, polymorphs, salts, crystal forms, compositions, methods of treatment, manufacturing processes, and key claim limitations cannot be identified.

What are the enforceable claim elements and limits?

No independent or dependent claim numbering, claim wording, examples, or limitation structure is provided for RS53811. As a result, it is not possible to extract:

• the independent claim(s) scope (compound vs composition vs method)
• structural formula requirements (if any)
• range limits (dose, impurity, stability)
• product-by-process constraints
• specific clinical endpoint wording (if any)
• novelty hooks (new use, new salt/polymorph, new regimen)

How broad is the claim scope versus closest competitors?

No landscape inputs are provided for RS53811 (assignee, priority, INN/chemical name, CPC/IPC, filing dates, or citation network). A meaningful comparison to closest prior patents in Europe or the Balkans (EPO/WO family members and Serbian national filings) cannot be performed from the provided information.

What does the Serbia-specific landscape look like?

No Serbia register data is provided for RS53811 (publication number, dates, term, status: granted/pending/expired, continuation events, or licensing). Without those, it is not possible to map:

• whether RS53811 corresponds to a national phase entry of WO/EP applications
• whether there are parallel SPCs or patent term extensions in Serbia
• how enforcement posture differs across time (expiration, lapse, opposition outcomes if any)

What is the infringement risk map by mechanism (compound/composition/method)?

A risk map requires claim content plus knowledge of likely generics and their approval-relevant details (salt form, polymorph, excipients, dosage regimen). Those inputs are not present, so no infringement assessment can be produced.

---

Key Takeaways

• A complete, accurate scope-and-claims analysis for RS53811 requires the published patent document and claim text; those are not included in the provided material.
• A defensible patent landscape for RS53811 also requires bibliographic and family data (assignee, priority, WO/EP/other family links, IPC/CPC, and legal status in Serbia); those are not present.
• No claim boundary extraction, freedom-to-operate structure, or competitor comparison can be stated without the underlying document.

---

FAQs

1. Can RS53811 be analyzed without the published specification and claim text?
   No. Scope and enforceability depend on claim wording and definitions in the specification.

2. Does RS53811 relate to a compound, a formulation, or a method of treatment?
   Not determinable from the provided input.

3. Can a Serbia-only landscape be built without knowing the assignee and priority/family links?
   No. Landscape mapping requires family linkage and document identifiers.

4. Can competitor patents be identified without the drug identity (INN/chemical name) and CPC/IPC classification?
   No. Competitor discovery depends on technical identifiers.

5. Is there enough information to estimate remaining term or legal status for RS53811?
   No. Legal status and dates are not provided.

---

References

[1] None provided.